Deubiquitinating enzyme OTUB1 in immunity and cancer: Good player or bad actor?

Cancer Lett. 2022 Feb 1:526:248-258. doi: 10.1016/j.canlet.2021.12.002. Epub 2021 Dec 4.

Abstract

OTU domain-containing ubiquitin aldehyde-binding proteins 1 (OTUB1) is the most important element of the deubiquitinase OTU superfamily, which has been identified as an essential regulator of diverse physiological processes, such as DNA damage repair and cytokines secretion. Recently, we found that the pro-carcinogenesis role of OTUB1 and the relationship between OTUB1 and immune response have gradually become the research hot-spot. OTUB1 regulates NK/CD8 T cell activation, autoimmune diseases, PD-L1 mediated immune evasion, viral or bacterial infection related immune response and the occurrence and progression of various cancers via deubiquitinating and stabilizing related proteins. This review provides a comprehensive description about the role and regulatory axis of OTUB1. We can explore the balance between immune response and defense via regulating the level of OTUB1, and targeting OTUB1 might restrain the progression of cancers. This review highlights the experimental evidence that OTUB1 is a feasible and potential therapeutic target against various cancers progression and immune diseases or disorder.

Keywords: Cancer; Immunity; Inflammation; OTUB1; Treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / enzymology
  • CD8-Positive T-Lymphocytes / immunology
  • Deubiquitinating Enzymes / metabolism*
  • Humans
  • Neoplasms / enzymology
  • Neoplasms / immunology*

Substances

  • Deubiquitinating Enzymes
  • OTUB1 protein, human